Eberconazole

• Description :

  Eberconazole is a dichlorinated imidazole derivative with antifungal activity. Eberconazole is more effective than Clotrimazole (HY-10882), Ketoconazole (HY-B0105), and Miconazole (HY-B0454) . Eberconazole has potential for the study of dermatophytosis[1][2].

• UNSPSC :

  12352005

• Target :

  Fungal

• Type :

  Reference compound

• Related Pathways :

  Anti-infection

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Infection

• Assay Protocol :

  https://www.medchemexpress.com/eberconazole.html

• Solubility :

  10 mM in DMSO

• Smiles :

  ClC1=CC(CCC2=C(C3N4C=NC=C4)C=CC=C2)=C3C(Cl)=C1

• Molecular Formula :

  C18H14Cl2N2

• Molecular Weight :

  329.22

• References & Citations :

  [1]Fernández-Torres B, et al. In vitro activities of the new antifungal drug eberconazole and three other topical agents against 200 strains of dermatophytes. J Clin Microbiol. 2003;41 (11) :5209-5211. |[2]Moodahadu L S, et al. Preclinical pharmacological profile of Eberconazole: A review and update[J]. Muller Journal of Medical Sciences and Research, 2014, 5 (2) : 159-165.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [128326-82-9]